A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States

Table 2 A summary of organic-mercury exposure from Thimerosal-containing hepatitis B vaccine administration among ASD cases and controls in the VSD database

Group examined	Number of cases diagnosed with ASD (%)	Number of controls without an ASD (%)	Odds ratio (95% CI)	p-value
*Experiment I*
12.5 μg organic-mercury within 1st month	155 (50.49)	8,161 (31.84)
			2.18 (1.74–2.73)	< 0.00001
0 μg organic mercury within 1st month	152 (49.51)	17,471 (68.16)
*Experiment II*
25 μg organic-mercury within first 2 months	154 (50.49)	8,172 (32.55)
			2.11 (1.68–2.64)	< 0.0001
0 μg organic-mercury within first 2 months	151 (49.51)	16,935 (67.45)
*Experiment III*
37.5 μg organic-mercury within first 6 months	30 (76.92)	1,073 (49.54)
			3.39 (1.60–7.18)	< 0.001
0 μg organic-mercury within first 6 months	9 (23.08)	1,093 (50.46)

ISSN: 2047-9158